Search the Newsreel

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile

Janux Therapeutics (JANX) saw its stock rise by 7.1% after announcing a narrower net loss for the second quarter and first half of 2026. The company reported a net loss of US$21.97 million, or US$0.35 per share, in Q2 2026, an improvement from US$33.86 …

Janus Living prices 16 million-share follow-on offering at $29 per share

Janus Living has priced a public offering of 16 million shares of Class A-1 common stock at $29 per share, with an option for underwriters to purchase an additional 2.4 million shares. The offering is expected to close on August 12, 2026, and proceeds …

Janus Living to Use 16M-Share Offering Proceeds for Acquisitions

Janus Living Announces Pricing of Public Offering of Class A-1 Common Stock

Janus Living, Inc. (NYSE: JAN) has announced the pricing of its public offering of 16,000,000 shares of Class A-1 common stock at $29.00 per share. The company has also granted underwriters a 30-day option to purchase an additional 2,400,000 shares. The proceeds from this …

RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating

RBC Capital Markets has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating on the stock. This adjustment reflects RBC's continued positive outlook on the company.

Janus Living Expects New Share Offering to Fund Acquisitions

Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results

Janux Therapeutics, Inc. (NASDAQ:JANX) missed its latest quarterly earnings expectations, with revenues significantly lower than forecasts and per-share losses exceeding predictions. As a result, analysts have reduced their revenue estimates for 2026 and increased their loss per share forecasts, though the consensus price target …

Janus Henderson Group PLC Cuts Stake in Janus International Group, Inc. $JBI

Janus Henderson Group PLC significantly reduced its stake in Janus International Group, Inc. (NYSE:JBI) by 87.0% in the first quarter, selling 2.36 million shares and retaining 354,174 shares. Despite this, other institutional investors increased their holdings, with institutional ownership reaching 88.78%. The company reported …

Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Janus Living (NYSE:JAN) - Stock Analysis

This Simply Wall St report provides a detailed stock analysis of Janus Living, Inc. (NYSE:JAN), a U.S. publicly traded REIT focused on senior housing. The analysis covers the company's valuation, future growth prospects (forecasted 114.52% annual earnings growth), past performance, financial health, dividends, management, …

Sei Investments Co. Has $2.67 Million Stock Holdings in Janus International Group, Inc. $JBI

Sei Investments Co. significantly increased its stake in Janus International Group, Inc. (NYSE:JBI) by 83.3% in the first quarter, now holding 517,883 shares valued at approximately $2.67 million. Institutional investors collectively own 88.78% of JBI's outstanding stock. Despite missing earnings per share estimates, the …

Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $22.00. While other analysts like William Blair also issued a Buy rating, Barclays maintained a Sell rating. The company recently reported a quarterly …

JAN Q2 Earnings Call Highlights

Key Points Interested in JAN? Here are five stocks we like better. Strong second-quarter results: Revenue rose 45% year over year, adjusted EBITDA increased 34%, and adjusted FFO per share grew 40%, supported by organic growth and approximately $800 million of first-half acquisitions. Operational …

Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside

Janux Therapeutics, Inc.'s average 12-month price target has been slightly reduced by analysts from $33.56 to $33.25, with a range of $14 to $60 per share. Despite the cut, the new target still implies a significant 107% potential upside based on the Aug. 6 …

İHLAS HABER AJANSI A.Ş.(IHAAS) Katılım Finansı İlkeleri Bilgi Formu 7 Ağustos 2026

Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue

Janux Therapeutics reported a Q2 2026 net loss of $22.0 million, narrowing from $33.9 million a year prior, driven by $10.3 million in collaboration revenue from its Bristol-Myers Squibb agreement. For the first half of 2026, the company recorded $14.0 million in collaboration revenue …

Jangada Mines Wins Strong Shareholder Backing at AGM

Janus International Group, Inc. $JBI Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in Janus International Group, Inc. by 12.7% in the first quarter, acquiring 474,205 additional shares, bringing their total ownership to 3.03%. Despite this institutional investment, analyst sentiment for JBI is largely cautious, with an average "Hold" rating …

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics reported its financial results for the second quarter of 2026, highlighting continued progress across its clinical programs, including JANX007, JANX014, and JANX011. The company maintains a strong financial position with $970.9 million in cash and investments and anticipates several key clinical milestones …

Jantra Grupo (KAQI) Tambah Dua Cabang, Laba Semester I-2026 Melonjak 67,9%

Anjani Portland Cement Ltd is Rated Strong Sell

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) reported a Q2 loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, though it improved from a $0.55 loss a year ago. The company also missed revenue estimates, posting $10.27 million against an expectation of …

Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates

Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M

Janux Therapeutics, Inc. (JANX) reported its Q2 revenue at $10.3 million, falling short of the FactSet estimate of $19.1 million. The article also mentions other recent news concerning the company, including a report of earnings results for the second quarter and six months ended …

BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35

Janux Therapeutics reported a Q2 basic EPS of USD -0.35. The article, sourced from Reuters, provides this brief financial update.

Ajanta Pharma shares decline 2.05% at Rs 3,452.70 on Wednesday morning

Janus Living, Inc. 2Q 2026: Revenue $216.5M, EPS $0.05— 10-Q Summary

IPO and follow-on fuel Janus Living (NASDAQ: JAN) as it posts $14,858 Q2 profit

JAN Stock Price and Chart — NYSE:JAN

This article provides an overview of Janus Living, Inc. (NYSE: JAN), a senior housing real estate investment trust. It details key financial statistics, including market capitalization, dividend yield, and recent earnings, highlighting significant revenue growth and raised guidance. The article also covers analyst ratings, …

Cooke & Bieler (JBI) discloses 5.10M Janus International shares in 13G/A

Cooke & Bieler L.P. filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,099,757 shares of Janus International Group, Inc. common stock, which represents 3.7% of the class. The firm reports shared voting power over 4,863,180 shares and shared dispositive power over all …

Press Release: Janus Living Reports Second Quarter 2026 Results and Increases Full Year 2026 Guidance

Janus Living announced its second quarter 2026 financial results, reporting strong performance that led to an increase in its full-year 2026 guidance. The company's positive financial trajectory indicates a successful first half of the year and confidence in continued growth. This updated outlook suggests …

Janus Living (NASDAQ: JAN) lifts 2026 guidance after Q2 revenue jumps 45%

Janus Living (NASDAQ: JAN) reported strong Q2 2026 results, with consolidated revenues up 45% year-over-year to $216 million and diluted EPS reaching $0.05. The company also announced significant portfolio expansion through acquisitions totaling $1.8 billion year-to-date and raised its full-year 2026 guidance for diluted …

Amrutanjan Health Care commissions ₹150 cr Telangana sanitary napkin plant

Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside

Janux Therapeutics (JANX) is a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer, showing a potential upside of over 142% according to analysts. Despite negative financial metrics typical of early-stage biotech firms, Janux benefits from strategic collaborations with major pharmaceutical companies and a robust …

Earnings Flash (JAN) Janus Living Posts Q2 Adjusted FFO $0.24, vs. FactSet Est of $0.25